View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsVeradigm 향후 성장Future 기준 점검 0/6Veradigm 의 수익과 수익은 각각 연간 0.5% 및 30.4% 감소할 것으로 예상됩니다. EPS는 연간 18.4% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -4.3% 로 예상됩니다.핵심 정보-30.4%이익 성장률-18.37%EPS 성장률Healthcare Services 이익 성장23.8%매출 성장률-0.5%향후 자기자본이익률-4.30%애널리스트 커버리지Low마지막 업데이트08 Feb 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Feb 13Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey SolutionVeradigm announced a new patient-reported outcomes (PRO) survey capability that brings the patient voice directly into real-world evidence generation. The new solution gives life sciences organizations timely, privacy-preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm's FollowMyHealth patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project-specific requests through trusted channels within FollowMyHealth, ensuring responses are authentic and relevant. Targeting logic helps reach the right patients quickly, and integrated consent and compensation streamline participation. Connecting the Full Patient Journey: Because of its nationally representative, diverse healthcare provider footprint, Veradigm is uniquely positioned to combine first-party clinical data from independent practices with direct patient input and point-of-care reach. This connected view helps innovators understand what truly drives outcomes and act with greater confidence. In 2025, Veradigm successfully completed and published a study demonstrating the feasibility of collecting PROs through FollowMyHealth and linking them with real-world data. The study validated the approach and confirmed the value of capturing patient experience alongside clinical information. By adding patient-reported information to existing real-world data, life sciences organizations gain a fuller picture of symptom burden, treatment experience, adherence, and quality-of-life factors. Benefits include: Patient-centered insights often missing from clinical documentation; Connected clinical and patient input for richer context; Trusted engagement through an established patient platform; Precision outreach to relevant patient groups; Integrated consent and compensation to reduce friction.New Risk • Feb 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 30% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Earnings are forecast to decline by an average of 30% per year for the foreseeable future.공시 • Jan 29Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent PracticesVeradigm announced the launch of a new AI-enabled application for Veradigm Revenue Cycle Services (RCS) clients, designed to deliver faster, deeper revenue cycle insights and strengthen the value of ongoing performance reviews for independent practices. Independent practices continue to face rising administrative complexity and financial pressure, driven by denials, payment variability, staffing constraints, and limited analytic visibility into what is driving revenue leakage. Veradigm RCS directly addresses these challenges by combining technology, expertise, and operational support to help practices improve cash flow and reduce revenue cycle burden. The new AI-enabled application is a web-based analytics workspace used by Veradigm's Revenue Cycle Services teams as part of their performance review process with clients. Instead of manually preparing and stitching together reports, analysts can now access an AI-generated view of denial trends, payment patterns, and operational bottlenecks in a single interface. The system automatically highlights anomalies, expands audit coverage, and surfaces emerging issues, allowing practices to see what is driving revenue leakage and where intervention is needed. Veradigm's new AI-enabled application is expected to reduce manual performance review preparation time by up to 25%, surface denial and payment trends automatically, and apply machine intelligence to expand audit coverage and reduce avoidable rework. Veradigm RCS is an end-to-end revenue cycle management solution designed to optimize financial performance for medical practices, with teams supporting everything from communicating with health plans to coding and claims, while integrating into existing electronic health record (EHR) and practice management workflows. Veradigm RCS consistently delivers top-tier financial outcomes for independent practices, achieving a 98% first-pass clean claims rate, 99% net collections, and 3-5% average revenue improvement in the first year.공시 • Jan 16Veradigm and Meperia Launch Industry-First 8-Way Match EDI Platform to Strengthen Healthcare Supply Chain IntegrityVeradigm and Meperia announced a strategic collaboration to launch a next-generation Electronic Data Interchange (EDI) solution, purpose-built for healthcare. This new EDI platform is designed to eliminate the friction, cost, and complexity of traditional EDI platforms through an industry-first 8-Way Match Framework. Built on a secure, cloud-based infrastructure supporting more than 16 million transactions, $5 billion in purchase volume, and unlimited supplier connections, the platform delivers hospital-first data governance tailored to provider needs and healthcare sustainability goals. The solution automatically validates each transaction against contracts, receipts, invoices, item masters, and rebate terms--minimizing errors, preventing overpayments, ensuring contract compliance, and enhancing rebate capture--all without manual intervention. By combining Veradigm's healthcare ERP platform spanning finance, supply chain, and point-of-use workflows, with Meperia's expertise in data governance, the collaboration delivers true end-to-end supply chain integrity.이익 및 매출 성장 예측BST:AL21 - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2026585N/AN/AN/A112/31/2025585N/AN/AN/A212/31/2024591-46-59-24312/31/20236146475105312/31/2022588-2083116N/A9/30/20221,52911682161N/A6/30/20221,522125107189N/A3/31/20221,512148-91-11N/A12/31/2021577128-118-77N/A9/30/2021806-14-373-319N/A6/30/20211,027-48-388-322N/A3/31/20211,255-96-183-98N/A12/31/2020556-28-149-104N/A9/30/20201,428-143-1584N/A6/30/20201,507-134-4467N/A3/31/20201,582-263-7937N/A12/31/20191,633-238-7446N/A9/30/20191,763-197-11920N/A6/30/20191,751-203-138-1N/A3/31/20191,74834-12915N/A12/31/20181,618-39-6668N/A9/30/20181,5167073188N/A6/30/20181,53354105237N/A3/31/20181,518-187120262N/A12/31/20171,498-183122279N/A9/30/20171,714-21067257N/A6/30/20171,657-19165246N/A3/31/20171,618-48105269N/A12/31/20161,38631145269N/A9/30/20161,470-2N/A268N/A6/30/20161,4323N/A255N/A3/31/20161,39710N/A229N/A12/31/20151,386-2N/A212N/A9/30/20151,382-21N/A180N/A6/30/20151,373-41N/A154N/A3/31/20151,372-56N/A141N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: AL21 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -30.4%).수익 vs 시장: AL21 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -30.4%).고성장 수익: AL21 의 수익은 향후 3년간 감소할 것으로 예상됩니다.수익 대 시장: AL21 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.5%).고성장 매출: AL21 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -0.5%).주당순이익 성장 예측향후 자기자본이익률미래 ROE: AL21는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/16 05:09종가2026/02/10 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Veradigm Inc.는 29명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jasper HellwegArgus Research CompanyMatthew GillmorBairdLawrence MarshBarclays26명의 분석가 더 보기
공시 • Feb 13Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey SolutionVeradigm announced a new patient-reported outcomes (PRO) survey capability that brings the patient voice directly into real-world evidence generation. The new solution gives life sciences organizations timely, privacy-preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm's FollowMyHealth patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project-specific requests through trusted channels within FollowMyHealth, ensuring responses are authentic and relevant. Targeting logic helps reach the right patients quickly, and integrated consent and compensation streamline participation. Connecting the Full Patient Journey: Because of its nationally representative, diverse healthcare provider footprint, Veradigm is uniquely positioned to combine first-party clinical data from independent practices with direct patient input and point-of-care reach. This connected view helps innovators understand what truly drives outcomes and act with greater confidence. In 2025, Veradigm successfully completed and published a study demonstrating the feasibility of collecting PROs through FollowMyHealth and linking them with real-world data. The study validated the approach and confirmed the value of capturing patient experience alongside clinical information. By adding patient-reported information to existing real-world data, life sciences organizations gain a fuller picture of symptom burden, treatment experience, adherence, and quality-of-life factors. Benefits include: Patient-centered insights often missing from clinical documentation; Connected clinical and patient input for richer context; Trusted engagement through an established patient platform; Precision outreach to relevant patient groups; Integrated consent and compensation to reduce friction.
New Risk • Feb 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 30% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Earnings are forecast to decline by an average of 30% per year for the foreseeable future.
공시 • Jan 29Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent PracticesVeradigm announced the launch of a new AI-enabled application for Veradigm Revenue Cycle Services (RCS) clients, designed to deliver faster, deeper revenue cycle insights and strengthen the value of ongoing performance reviews for independent practices. Independent practices continue to face rising administrative complexity and financial pressure, driven by denials, payment variability, staffing constraints, and limited analytic visibility into what is driving revenue leakage. Veradigm RCS directly addresses these challenges by combining technology, expertise, and operational support to help practices improve cash flow and reduce revenue cycle burden. The new AI-enabled application is a web-based analytics workspace used by Veradigm's Revenue Cycle Services teams as part of their performance review process with clients. Instead of manually preparing and stitching together reports, analysts can now access an AI-generated view of denial trends, payment patterns, and operational bottlenecks in a single interface. The system automatically highlights anomalies, expands audit coverage, and surfaces emerging issues, allowing practices to see what is driving revenue leakage and where intervention is needed. Veradigm's new AI-enabled application is expected to reduce manual performance review preparation time by up to 25%, surface denial and payment trends automatically, and apply machine intelligence to expand audit coverage and reduce avoidable rework. Veradigm RCS is an end-to-end revenue cycle management solution designed to optimize financial performance for medical practices, with teams supporting everything from communicating with health plans to coding and claims, while integrating into existing electronic health record (EHR) and practice management workflows. Veradigm RCS consistently delivers top-tier financial outcomes for independent practices, achieving a 98% first-pass clean claims rate, 99% net collections, and 3-5% average revenue improvement in the first year.
공시 • Jan 16Veradigm and Meperia Launch Industry-First 8-Way Match EDI Platform to Strengthen Healthcare Supply Chain IntegrityVeradigm and Meperia announced a strategic collaboration to launch a next-generation Electronic Data Interchange (EDI) solution, purpose-built for healthcare. This new EDI platform is designed to eliminate the friction, cost, and complexity of traditional EDI platforms through an industry-first 8-Way Match Framework. Built on a secure, cloud-based infrastructure supporting more than 16 million transactions, $5 billion in purchase volume, and unlimited supplier connections, the platform delivers hospital-first data governance tailored to provider needs and healthcare sustainability goals. The solution automatically validates each transaction against contracts, receipts, invoices, item masters, and rebate terms--minimizing errors, preventing overpayments, ensuring contract compliance, and enhancing rebate capture--all without manual intervention. By combining Veradigm's healthcare ERP platform spanning finance, supply chain, and point-of-use workflows, with Meperia's expertise in data governance, the collaboration delivers true end-to-end supply chain integrity.